Skip to main content
. 2022 Jul 11;63:101544. doi: 10.1016/j.molmet.2022.101544

Figure 4.

Figure 4

D-BAT attenuates tumor-associated AT browning and lipolysis. C57BL/6 female mice (N = 5), pre-treated with D-BAT or PBS (control) over 3 weeks, were grafted with tumors and then injected with D-BAT or PBS for 2 more weeks. (A) BAT, tumor-distal SAT, tumor-proximal VAT and tumors from representative mice. (B) Quantification of tissue mass from all mice (N = 5). Plotted are mean ± SEM; ∗P < 0.05, (Student's t-test). (C) IF with UCP1/red fluorescence secondary antibodies and perilipin1/green fluorescence secondary antibodies. Arrow: beige AT. (D) IF analysis with UCP1/red fluorescence secondary antibodies and co-stained with isolectin B4 (green) marking endothelium. Arrow: beige AT. (E) IF with phosphorylated hormone-sensitive lipase (pHSL)/red-fluorescent secondary antibodies and perilipin1/green-fluorescent secondary antibodies. Note browning (UCP1 expression) and lipolysis (pHSL expression, arrows) in BAT and tumor-proximal AT, which is reduced by D-BAT treatment but not by PBS. Nuclei are blue. Scale bars: 50 μm.